ReviewClinical drug investigation2025

Resmetirom: The First FDA-Approved Drug for Metabolic Dysfunction-Associated Steatohepatitis (MASH) with a Perspective on Precision Medicine.

Fengshuo Zhang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.